Skip to Main Content

September 15, 2023    
Health Law Weekly

FTC to Scrutinize Improper Drug Patent Listings in Orange Book

  • September 15, 2023

Improper patent listings of brand-name drugs in the Food and Drug Administration’s (FDA’s) “Orange Book” may be viewed as unfair methods of competition under federal antitrust law, the Federal Trade Commission (FTC) warned pharmaceutical companies in a policy statement issued September 14.


You must be logged in to access this content.